The new lab at the Innovation and Start-Up Center for Biotechnology (IZB) in Munich serves as a strategic hub for Novogene's European operations and builds on its global network of labs across the UK, US, Singapore, Japan and China. The addition of the Revio will complement Novogene's existing sequencing portfolio, giving customers answers where other technologies have been unable to, due to depth or accuracy limitations. As well as rare disease and cancer research, Novogene anticipates high demand for the ...

文章核心观点 - PacBio宣布诺禾致源使用其Revio长读长测序系统扩展德国慕尼黑新实验室能力，为欧洲科学界客户服务，该系统能助力客户以经济方式开展多领域基因组研究 [1] 合作情况 - 诺禾致源是领先基因组服务和生物信息学专业机构，与众多研究、临床和商业组织合作，其慕尼黑新实验室将Revio加入现有测序产品组合，为客户提供其他技术无法提供的答案 [1][2] - PacBio副总裁认为Revio高精度适合支持诺禾致源客户，特别是探索复杂生物应用的客户，与诺禾致源合作能让Revio用于前沿应用 [3] 系统优势 - Revio的高准确性和通量可使诺禾致源客户在罕见病、癌症、微生物和农业等领域开展深入基因组研究 [1] - 诺禾致源副总裁称Revio能揭示短读长和外显子组方法通常遗漏的复杂重复区域、结构变异和新异构体，其高保真度结合PacBio各种试剂盒和数据分析能力，能以经济方式为客户提供长读长数据 [2] 公司信息 - PacBio是领先生命科学技术公司，设计、开发和制造先进测序解决方案，产品基于HiFi长读长测序和SBB短读长测序两项核心技术，应用于多领域研究 [4] - 诺禾致源是领先基因组服务和解决方案提供商，拥有世界领先测序能力，近2000名员工、全球多地有业务、66项NGS相关专利、超22000篇顶级期刊出版物，服务由Illumina、PacBio和Oxford Nanopore Technology最新平台支持 [7]

文章核心观点 PacBio宣布将于2024年8月7日下午4:30（东部时间）举行季度电话会议，讨论2024年第二季度财务结果 [3] 公司信息 - 公司是一家领先的生命科学技术公司，设计、开发和制造先进测序解决方案，帮助科学家和临床研究人员解决基因复杂问题 [2] - 产品和技术源于两个高度差异化的核心技术，包括HiFi长读长测序和SBB®短读长测序技术 [2] - 产品适用于广泛的研究应用，包括人类生殖系测序、动植物科学、传染病和微生物学、肿瘤学等新兴应用 [2] - 产品仅供研究使用，不可用于诊断程序 [5] 会议信息 - 会议时间为2024年8月7日下午4:30（东部时间），即下午1:30（太平洋时间） [3] - 可通过网络直播收听，网址为https://investor.pacificbiosciences.com/ [1][3] - 拨入号码：免费电话1 - 888 - 349 - 0136，国际电话1 - 412 - 317 - 0459 [3] 联系方式 - 媒体联系邮箱：pr@pacb.com [3] - 投资者联系：Todd Friedman，邮箱ir@pacb.com [5]

文章核心观点 PacBio宣布将于2024年8月7日下午4:30（东部时间）举行季度电话会议，讨论2024年第二季度财务结果 [1] 会议信息 - 会议时间为2024年8月7日下午4:30（东部时间），即下午1:30（太平洋时间） [1] - 直播或回放链接为https://investor.pacificbiosciences.com/ [1][2] - 免费电话为1 - 888 - 349 - 0136，国际电话为1 - 412 - 317 - 0459 [1] - 若选择拨入方式，需在会议开始前十分钟使用上述号码并要求加入“PacBio Q2 Earnings Call” [3] 公司信息 - 公司是一家领先的生命科学技术公司，设计、开发和制造先进测序解决方案，帮助科学家和临床研究人员解决基因复杂问题 [3] - 产品和技术源于HiFi长读长测序和SBB®短读长测序两项核心技术，专注于准确性、质量和完整性 [3] - 产品应用广泛，涵盖人类生殖系测序、动植物科学、传染病和微生物学、肿瘤学等领域 [3] - 公司网址为www.pacb.com，可关注@PacBio获取更多信息 [3] 联系方式 - 投资者联系Todd Friedman，邮箱为ir@pacb.com [2] - 媒体联系邮箱为pr@pacb.com [4] 产品说明 - 公司产品仅供研究使用，不可用于诊断程序 [2]

文章核心观点 - 公司PacBio与Form Bio合作,共同成立AAV工作组,旨在推动AAV行业的标准化和协作 [1][2][3][4] - PacBio拥有HiFi长读长测序和SBB短读长测序两大核心技术,正在不断拓展其基因组解决方案 [5][6][7] - 长读长测序市场预计未来将保持30.92%的高速增长,受益于遗传疾病和个性化医疗的需求增加 [8][9] - PacBio近期推出了针对神经系统疾病的重复扩张基因检测产品,以及适用于多种样本类型的DNA提取试剂盒 [10][11] - 受整体市场环境影响,PacBio股价在过去6个月内大幅下跌86% [12] 行业概况 - 长读长测序市场规模在2022年达到4.551亿美元,预计未来将以30.92%的年复合增长率快速增长 [8] - 市场增长的主要驱动因素包括遗传疾病和染色体紊乱的高发病率、个性化医疗的兴起,以及新技术的不断涌现 [9] 公司概况 - PacBio是一家生命科学技术公司,专注于开发先进的基因测序解决方案 [5] - 公司拥有HiFi长读长和SBB短读长两大核心技术,正在不断推出新产品和技术 [5][6][7] - 近期推出了针对神经系统疾病的重复扩张基因检测产品,以及适用于多种样本类型的DNA提取试剂盒 [10][11] - 受整体市场环境影响,公司股价在过去6个月内大幅下跌86% [12] 同行业公司表现 - DaVita、Ecolab和Universal Health Services等同行业公司近期业绩表现良好 [14][15][16][17] - DaVita和Ecolab的股价在过去一年内分别上涨44%和33.8%,优于行业整体水平 [15][16] - Universal Health Services的每股收益增长率预计将达到30.5% [17]

Pacific Biosciences of California (PACB) closed the latest trading day at $1.37, indicating a +0.74% change from the previous session's end. This move outpaced the S&P 500's daily loss of 0.41%. Elsewhere, the Dow saw a downswing of 0.12%, while the tech-heavy Nasdaq depreciated by 0.71%. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate ...

Consortium Delivers Publicly Available Datasets that Enrich Detection of Rare and Novel Genetic Variants for Advances in Human Disease Research "Joining forces with PacBio has enabled us to leverage their HiFi sequencing capabilities, enhancing the depth and accuracy of the genomic data we can offer to the research community," said Michael Schatz, Bloomberg Distinguished Professor at Johns Hopkins University. "This effort complements existing databases such as gnomAD, as long reads enable much greater sensi ...

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, has been gaining from its continued focus on research and development. The optimism, led by a decent first-quarter 2024 performance and its product development activities, is expected to contribute further. However, stiff competition and macroeconomic concerns persist. In the year-to-date period, this Zacks Rank #3 (Hold) stock has lost 80.9% against 6.9% growth of the industry. The S&P 500 Composite also gained 11.6% in the same ti ...

Pacific Biosciences of California (PACB) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Earnings Estimate Revisions Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. We ...

Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center Program ALISO VIEJO, Calif. and MENLO PARK, Calif., May 15, 2024 /PRNewswire/ --Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced their companies' selection by the University of California, Irvine (UCI) and the GREGoR Consortium (Genom ...